These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 14739059)
1. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059 [TBL] [Abstract][Full Text] [Related]
2. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Gadducci A; Tana R; Cosio S; Genazzani AR Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182 [TBL] [Abstract][Full Text] [Related]
3. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Takeda M; Sakuragi N; Okamoto K; Todo Y; Minobe S; Nomura E; Negishi H; Oikawa M; Yamamoto R; Fujimoto S Acta Obstet Gynecol Scand; 2002 May; 81(5):451-7. PubMed ID: 12027820 [TBL] [Abstract][Full Text] [Related]
4. Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gadducci A; Tana R; Fanucchi A; Genazzani AR Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924 [TBL] [Abstract][Full Text] [Related]
5. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681 [TBL] [Abstract][Full Text] [Related]
6. Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment. Suzuki Y; Tokinaga-Uchiyama A; Mizushima T; Maruyama Y; Mogami T; Shikata N; Ikeda A; Yamamoto H; Miyagi E BMC Cancer; 2018 Oct; 18(1):973. PubMed ID: 30314462 [TBL] [Abstract][Full Text] [Related]
7. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543 [TBL] [Abstract][Full Text] [Related]
8. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184 [TBL] [Abstract][Full Text] [Related]
9. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544 [TBL] [Abstract][Full Text] [Related]
10. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix. Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362 [TBL] [Abstract][Full Text] [Related]
11. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Suzuki M; Ohwada M; Sato I; Nagatomo M Oncology; 1995; 52(2):128-33. PubMed ID: 7854772 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 serum levels in patients with gynecological tumors. Scambia G; Testa U; Panici PB; Martucci R; Foti E; Petrini M; Amoroso M; Masciullo V; Peschle C; Mancuso S Int J Cancer; 1994 May; 57(3):318-23. PubMed ID: 8168990 [TBL] [Abstract][Full Text] [Related]
13. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix. Gocze PM; Vahrson HW; Freeman DA Oncology; 1994; 51(5):430-4. PubMed ID: 8052484 [TBL] [Abstract][Full Text] [Related]
14. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients. Tempfer C; Hefler L; Haeusler G; Reinthaller A; Koelbl H; Zeisler H; Kainz C Int J Cancer; 1998 Jun; 79(3):241-4. PubMed ID: 9645344 [TBL] [Abstract][Full Text] [Related]